Group 1 - The core point of the news is the appointment of He Fangzhou as a new fund manager for the Wanjiac Fund Management Co., Ltd.'s Hong Kong Stock Connect Innovative Drug ETF (520700) [1] - He Fangzhou has a background in fund operations and research, having previously worked at Huatai-PineBridge Fund Management Co., Ltd. and Da Cheng Fund Management Co., Ltd. [1] - The Wanjiac Hong Kong Stock Connect Innovative Drug ETF was established on September 13, 2024, and has shown a year-to-date return of 61.08% and a cumulative return of 43.25% since its inception, with a net asset value of 1.4325 yuan as of June 24, 2025 [1] Group 2 - The fund is officially named Wanjiac Hong Kong Stock Connect Innovative Drug Exchange-Traded Fund, with the main code 520700 [3] - The announcement is made in accordance with the "Publicly Raised Securities Investment Fund Information Disclosure Management Measures" [3] - The fund is co-managed by He Fangzhou and Yang Kun [3]
万家中证港股通创新药ETF增聘贺方舟
Zhong Guo Jing Ji Wang·2025-08-08 07:16